What an IBAT inhibitor, a successful Phase III program, and...
Read MoreWhere biopharma strategy meets science. I write about AI in drug discovery, BD deal-making, and the harder questions behind the headlines — for VCs, founders, and operators navigating where biotech goes next.
Read the latest below
What an IBAT inhibitor, a successful Phase III program, and...
Read MoreHow systems biology and network medicine may help solve the...
Read MoreJoin readers in biotech venture, pharma BD, and drug discovery strategy who get my take first.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
These cookies are needed for adding comments on this website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)
You can find more information in our Terms of Use and .